Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol-Enhanced MRI for Osteonecrosis
NCT02893293Phase 4Completed
- Sponsor
- Stanford University
- Start
- May 2015
- Primary completion
- Oct 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ferumoxytol in osteonecrosis (2 arms), sponsored by Stanford University. Primary endpoints: Signal to Noise Ratio at 1 week, T2*-Relaxation Time at 1 week and 1 more. Started May 2015; status: completed.
02
Drugs
ferumoxytol
03
Conditions
osteonecrosis
Beyond the preview
Go deeper on NCT02893293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893293.